No fewer than nine volunteers took part in today’s event, showed Venketesh Chaturvedi, executive director of the PTI news agency. “The trials began under the supervision of Dr. Ajit Pratap Singh and the gynecologist and obstetrician Dr. Sona Ghosh,” Chaturvedi said. Those who took the vaccine today were under strict surveillance. “Surely everyone’s fine,” he added.
On Monday, the clinical trial of the COVID-19 candidate vaccine in India, Covaxin, began at the Institute of Medical Sciences and Sum Hospital in Bhubaneswar. Several other people took the dose of the coronavirus vaccine at the hospital, said Dr. E Venkat Rao, lead researcher of the trial process. The selected volunteers will get two doses within 14 days, Rao said. “There’s a lot of enthusiasm among those who volunteered for the trial,” he added.
The first phase of the human Covaxin trial ended in PGIMS Rohtak. The hospital began testing on July 17 and about 50 volunteers registered for the exercise. “Another 50 people in India have won the vaccine and the effects have been encouraging,” Dr. Savita Verma, lead researcher on the vaccine’s test team, told the ANI news agency.
In the first phase of the trial, volunteers over 18 to 55 years old will participate without comority situations. There are 3 formulas of the COVID-19 candidate vaccine. Each theme will get any of the formulas in two takes two weeks apart. The first 50 will get the lowest dose of the vaccine. If found to be safe, they will be given to another 50 patients at the maximum doses, said Dr. Sanjay Rai, a professor at the AIIMS Center for Community Medicine, according to the PTI news agency.
At least 375 other people will participate in the early stages of the human clinical trial of the first COVID-19 vaccine in India. More than 3,500 volunteers have already registered for the test. Twelve institutes have been decided across the country for the first circular of trials.
Covaxin evolved through Bharat Biotech International Limited with the Indian Medical Research Council and the National Institute of Virology. Bharat Biotech has developed an “inactivated” vaccine at its high-containment genome valley facility in Hyderabad. In addition to Uttar Pradesh, vaccine testing has already begun in Hyderabad, Rohtak, Patna, Kancheepuram, Delhi, Goa and Bhubaneswar.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.